Related Experiment Videos
Type II estrogen binding sites (EBS) in intracranial tumors
A Capelli1, M Piantelli, A Rinelli
1Istituti di Anatomia Patologica, Università Cattolica del S. Cuore, Roma, Italy.
Journal of Neurosurgical Sciences
|July 1, 1990
Summary
This study investigated estrogen receptors (ER), progesterone receptors (PgR), and estrogen binding sites (EBS) in brain tumors. Results indicate these tumors may exhibit hormonal sensitivity due to the presence of these receptors and binding sites.
Area of Science:
- Neuro-oncology
- Endocrinology
- Molecular Biology
Background:
- Meningiomas and neuroepithelial tumors are primary brain tumors.
- Hormone receptor status is crucial for understanding tumor biology and potential therapeutic targets.
Purpose of the Study:
- To determine the presence and levels of estrogen receptors (ER), progesterone receptors (PgR), and type II estrogen binding sites (EBS) in meningiomas and neuroepithelial tumors.
- To explore the potential hormonal sensitivity of these tumor types.
Main Methods:
- Tissue samples from ten brain tumors (4 meningiomas, 6 neuroepithelial tumors) were analyzed.
- Quantification of ER, PgR, and type II EBS using biochemical assays.
Main Results:
- Estrogen receptors (ER) were detected in 70% of cases (2.5–20.7 fmoles/mg).
- Progesterone receptors (PgR) were present in all 10 cases (8.8–130.6 fmoles/mg).
- All samples showed significant levels of type II estrogen binding sites (EBS) (452–2320 fmoles/mg).
Conclusions:
- Meningiomas and neuroepithelial tumors frequently express ER, PgR, and type II EBS.
- The presence of these receptors and binding sites suggests potential hormonal sensitivity in these brain tumors.
- Further research is warranted to elucidate the functional role of type II EBS in tumor development.